Phase Forward Delivers Enhanced Integration Capabilities as Part of Ongoing Adapter Strategy
InForm Adapter, Available Immediately, Strengthens Integration with Existing Customer Data and Systems.
WALTHAM, Mass.-June 12, 2006-Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the new InForm™ Adapter module, providing customers with enhanced integration capabilities for the InForm Integrated Trial Management (ITM) electronic data capture (EDC) solution. With the InForm Adapter module, InForm ITM users can leverage a set of Web services-based interfaces to access data and event information stored in the InForm database. The result is a broader set of integrated and extensible clinical workflow solutions that better leverage InForm ITM users' existing proprietary systems and packaged applications.
The announcement reflects the company's strategy to deliver greater integration and extensibility for Phase Forward customers through adapters. Providing adapters that leverage Web services standards creates an architecture that allows more integration points to be added more quickly in the future.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
